Skip to main content
Local News

Alpine Immune Sciences Raising $100M in Public Offering

By October 3, 2022No Comments

Seattle-based biotech Alpine Immune Sciences (Nasdaq: ALPN) is raising $100 million through an underwritten public offering.

With the new funding, announced Tuesday, Alpine co-founder and CEO Mitchell Gold said the biotech now has more than three years of runway. He added that the company, which now has about 130 people, has grown 65% over the past nine months, but he didn’t provide a target headcount growth for the near future.